摘要
近十年来,与单药治疗或传统的阶梯治疗、序贯治疗等相比,两种或以上降压药物组成的单片复方制剂(SPC)可更有效地控制血压,并获国内外高血压指南的肯定和建议。2012年中华医学会心血管病学分会曾组织了有关SPC降压治疗的学术讨论,并发表了"单片复方制剂降压治疗中国专家共识"。数年过去,我国现阶段高血压的控制率仍然较低,SPC在降压药中的使用比例不高。不少降压达标率显著提升的成功经验显示,增加SPC使用率是提高血压达标率的主要途径之一。根据近年来国内外使用SPC的进展,中华医学会心血管病学分会组织有关专家对本共识文件进行修订,提出了SPC治疗流程建议,希望通过增加SPC的使用率提高我国降压达标率及高血压管理质量。
Single-pill combination therapy, usually consisting of 2 and above different classes of antihypertensive drugs, may exhibit better antihypertensive efficacy compared with monotherapy, traditional step-care, or sequential antihypertensive strategies. And many hypertension guidelines suggest the use of single-pill combination approach in the management of hypertension. However, the rates of application single-pill combinations and hypertension control are still low in China. Chinese Society of Cardiology, therefore, have organized a series of workshops on single-pill combination antihypertensive therapy, and they have developed the present consensus document which discussed systematically the importance and effectiveness of single-pill combination strategy and proposed definite medication suggestions on hypertension.
作者
陈鲁原
卢新政
Panel of Chinese Expert Consensus on Antihypertensive Therapy with Single-pill Combination;Chinese Society of Cardiology of the Chinese Medical Association
出处
《中华高血压杂志》
CAS
CSCD
北大核心
2019年第4期310-317,共8页
Chinese Journal of Hypertension
关键词
单片复方制剂
高血压
降压治疗
共识
single-pill combination
hypertension
antihypertensive therapy
consensus
